• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Prevention
  • Policy, Organisation and…
  • Adult Immunisation

The Socio-Economic Value of Adult Immunisation Programmes

The Socio-economic Value of Adult Immunisation Programmes
Read more
  • Antimicrobial Resistance (AMR)
  • Policy, Organisation and…
  • Quality of Life

Capturing the Broader Value of Antibiotics

STEDI Roadmap
Read more
  • Health Technology Assessment…
  • Economics of Innovation
  • Innovation

Innovation for Health System Efficiency and Improvement

Report picture
Read more
  • Drug Development/R&D
  • Value, Affordability, and…
  • Value based pricing

Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?

6
Read more
  • Antimicrobial Resistance (AMR)
  • Value, Affordability, and…

Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective

Proposal for a Novel Antimicrobial  Subscription
Read more
  • Health Care Systems
  • Policy, Organisation and…
  • Economic Evaluation

Reimagining Prevention for a Healthier, More Prosperous Society

Prev web
Read more
  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 18th November 2013

OHE Study Projecting UK Medicines Expenditure Extended to 2018

The extended analysis is outlined in the slide presentation in this post. PharmacoEconomics recently published OHE’s study projecting medicines expenditure in the UK to 2015. The PPRS 2014 Heads of Agreement was announced on 6 November 2013, which outlines the…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

The extended analysis is outlined in the slide presentation in this post.

PharmacoEconomics recently published OHE’s study projecting medicines expenditure in the UK to 2015. The PPRS 2014 Heads of Agreement was announced on 6 November 2013, which outlines the terms of the five-year deal between the pharmaceuctical industry and the government in the UK.

PharmacoEconomics recently published OHE’s study projecting medicines expenditure in the UK to 2015[1]. The PPRS 2014 Heads of Agreement was announced on 6 November 2013, which outlines the terms of the five-year deal between the pharmaceuctical industry and the government in the UK. For the first time in the UK, the PPRS caps future growth in the NHS’s branded medicines bill, between 2014 and 2018. OHE’s model for projecting NHS medicines expenditure was an important tool used by the Association of the British Pharmaceutical Industry (ABPI) to produce its forecast for discussion with the Department of Health.

OHE extended the model published in PharmacoEconomics to cover the evolution of NHS medicines expenditure until the end of 2018. The presentation below shows the projections for this longer period, which are based on the same methodology as in the PharmacoEconomics article. We will shortly publish an OHE Occasional Paper describing these results in greater detail.

UK NHS Medicines Bill Projection: Methodology and Results 2013-2018 from Office of Health Economics

Download: UK NHS Medicines Bill Projection: Methodology and Results 2013-2018

[1]O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J. (2013) Projecting expenditure on medicines in the UK NHS. 31(10), 933-957.

This journal article is a refinement of an OHE Research Paper available on this website. O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J. (2013) Projecting expenditure on medicines in the NHS. Research Paper 13/02. London: Office of Health Economics.

 

  • Pricing and Reimbursement

Related News

IRA-course-graphic-for-website-news-FINAL-1
  • News
  • May 2023

New free educational program launched – Explaining the U.S. Inflation Reduction Act

Read more
  • News
  • November 2021

Opportunity Cost in Health Care: a Favourite Research Topic for OHE

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!